Ruxolitinib Phosphate Cream Gains New Indication: Lumirix® Approved by NMPA for Patients Aged 2 and Older

Ruxolitinib phosphate cream gains new indication for atopic dermatitis. In September 2026, ruxolitinib phosphate cream (brand name: Opzelura®) gained a new indication in China for the treatment of mild-to-moderate atopic dermatitis (AD). According to an announcement issued by China Medical System Holdings, the product has received a Drug Registration Certificate from the National Medical Products Administration (NMPA) for eligible children aged 2 years and older and adults with mild-to-moderate atopic dermatitis.

✨ This approval marks the second approved indication for Opzelura® in China. Previously, the product was approved in January 2026 for the treatment of vitiligo. With this indication expansion, ruxolitinib phosphate cream now covers an additional dermatological treatment area in China, providing another topical treatment option for eligible patients with atopic dermatitis.

What Is Atopic Dermatitis and Why Does Mild-to-Moderate Atopic Dermatitis Still Require Attention?

Atopic dermatitis (AD) is a chronic, recurrent inflammatory skin disease commonly characterized by dry skin, itching, erythema, and skin lesions of varying severity. The condition tends to recur, and the severity, extent of skin involvement, and clinical manifestations can vary significantly between patients. As a result, treatment generally requires long-term management tailored to the individual patient’s condition.

Atopic dermatitis can affect both adults and children. Persistent itching and skin lesions may interfere with sleep, learning, work, and daily activities. For some patients, existing topical treatments may not provide adequate disease control, while others may not be suitable for continuing certain treatment approaches because of their individual treatment circumstances. These situations may create a need for additional treatment options.

Although mild-to-moderate atopic dermatitis is generally not considered the most severe form of the disease, this does not mean that its treatment needs should be overlooked. In particular, for patients with recurrent disease or inadequate control with topical treatment, achieving effective local control during periods of disease activity remains an important aspect of clinical management.

Therefore, the significance of the new mild-to-moderate atopic dermatitis indication for ruxolitinib phosphate cream is that it provides an additional topical treatment option for eligible children and adults who meet the approved criteria. It does not simply mean that the medicine is suitable for all patients with atopic dermatitis.

👉 For more information, please read this article：

What Triggers Atopic Dermatitis? A Guide to Symptoms, Treatment, and Daily Care for Atopic Dermatitis

What Is Ruxolitinib Phosphate Cream?

Ruxolitinib phosphate cream is a topical JAK inhibitor containing ruxolitinib as its active ingredient. It was developed by Incyte. Its international brand name is Opzelura®, while the product marketed in China is known as 百卢妥® (Lumirix). Unlike oral JAK inhibitors, this product is formulated as a topical cream and is primarily intended to act on affected areas of the skin.

Contact

From a pharmacological perspective, ruxolitinib belongs to the class of Janus kinase (JAK) inhibitors, with JAK1 and JAK2 as its main targets. The JAK signaling pathway is involved in the transmission of signals from various cytokines, some of which are associated with skin inflammation and immune responses. As a result, the JAK pathway has become an important area of drug development in the field of dermatological immunology in recent years.

As clinical research and regulatory approvals have progressed, ruxolitinib phosphate cream has been used for the treatment of specific dermatological conditions in different markets. In China, the product was previously approved for an indication related to vitiligo. With the addition of the mild-to-moderate atopic dermatitis indication, its application in the field of dermatology has been further expanded.

Key Product Information

Item	Details
Generic name	Ruxolitinib Phosphate Cream
Active ingredient	Ruxolitinib
Chinese brand name	百卢妥® (Lumirix)
Drug class	Topical JAK inhibitor
Primary targets	JAK1, JAK2
Dosage form	Cream
Route of administration	Topical application
Developer	Incyte
China-related company	Dermegis
Previously approved indication in China	Vitiligo
New indication in China	Mild-to-moderate atopic dermatitis
Approval date for the new indication	September 2026
Applicable age group	Children aged 2 years and older and adults

Based on its product characteristics, the key features of ruxolitinib phosphate cream include its topical formulation, JAK1/JAK2 targets, and application in the treatment of dermatological conditions. The approval of the new atopic dermatitis indication further expands the potential application of the product in dermatological immunotherapy.

It is important to note that the approved indications, age ranges, and usage requirements for ruxolitinib phosphate cream may vary between countries and regions. Therefore, when purchasing the medicine or seeking medical and pharmaceutical information, the latest official regulatory information and approved product labeling applicable to the relevant market should be consulted.

Key Pharmacological Characteristics of Ruxolitinib Phosphate Cream: Topical Inhibition of the JAK Pathway

The pharmacological basis of ruxolitinib phosphate cream is closely associated with the JAK-STAT signaling pathway. The JAK family primarily consists of JAK1, JAK2, JAK3, and TYK2. Different JAK proteins participate in the signaling of different cytokines, while JAK1 and JAK2 are involved in multiple inflammatory and immune-related signaling pathways and have therefore become important targets for certain targeted therapies.

Ruxolitinib inhibits signaling mediated by JAK1 and JAK2, thereby affecting downstream signaling associated with certain cytokines. In inflammatory skin diseases such as atopic dermatitis, abnormal immune and inflammatory signaling is an important component of disease development and progression. Modulating JAK-related signaling pathways has therefore become one therapeutic approach in the management of these conditions.

Unlike systemic oral JAK inhibitors, ruxolitinib phosphate cream is administered topically, with its formulation and use designed primarily for the treatment of affected areas of the skin. This topical administration is an important part of understanding the characteristics of Lumirix®.

However, target selection, topical administration, and pharmacological mechanisms should not be directly interpreted as evidence of superior clinical safety or efficacy. Actual treatment outcomes and safety need to be evaluated through clinical studies and should be considered in the context of the specific indication, individual patient characteristics, and the latest approved product labeling. Therefore, in pharmaceutical information materials, it is more appropriate to accurately describe ruxolitinib phosphate cream as a topical JAK inhibitor, rather than making broadly defined claims such as “safer” or “causes fewer side effects” without sufficient clinical qualification.

What Is the New Indication? Ruxolitinib Phosphate Cream Approved for Mild-to-Moderate Atopic Dermatitis

In September 2026, ruxolitinib phosphate cream (Opzelura®) received approval from the National Medical Products Administration (NMPA) in China for a new indication covering mild-to-moderate atopic dermatitis (AD). According to the approved indication, the product is intended for the short-term and non-continuous chronic topical treatment of mild-to-moderate atopic dermatitis in non-immunocompromised children aged 2 years and older and adults when other topical treatments have not provided adequate control or are not advisable.

The inclusion of children aged 2 years and older and adults is an important aspect of this new indication. Atopic dermatitis can occur at different stages of life, with children representing an important patient population. By explicitly covering children aged 2 years and older, the approval further defines the applicable age range of the product. However, being 2 years of age or older does not mean that every child with atopic dermatitis is automatically eligible for treatment. Whether the treatment is appropriate should be determined based on factors such as disease severity, previous topical treatment, immune status, and the latest approved product labeling.

In terms of treatment conditions, the new indication does not position ruxolitinib phosphate cream as a general replacement for other treatments in all patients with mild-to-moderate atopic dermatitis. Instead, it specifically applies when other topical treatments have not provided adequate control or are not advisable. This limitation illustrates the connection between an approved drug indication and its specific clinical treatment setting.

Phase III Clinical Study Provides Evidence for Ruxolitinib Phosphate Cream in Mild-to-Moderate Atopic Dermatitis

The approval of the new indication was supported by relevant clinical research data. A previously conducted Chinese Phase III clinical study was a randomized, double-blind, placebo-controlled, multicenter study involving 192 patients with mild-to-moderate atopic dermatitis. The study primarily evaluated the efficacy and safety of ruxolitinib phosphate cream in this patient population.

• After 8 weeks of treatment, the proportion of patients who achieved an Investigator’s Global Assessment (IGA) score of 0 or 1, with an improvement of at least 2 grades from baseline, was 63.0%, compared with 9.2% in the placebo group, with a statistically significant difference between the two groups.
• At the same time, 78.0% of patients achieved EASI-75, defined as at least a 75% improvement from baseline in the Eczema Area and Severity Index (EASI), compared with 15.4% in the placebo group. These findings indicate that, in this Chinese Phase III study, ruxolitinib phosphate cream met the predefined study objectives for the primary endpoint and key secondary endpoint.

Regarding safety, most treatment-emergent adverse events (TEAEs) reported during the study were mild or moderate in severity, and no TEAE led to discontinuation of the study treatment.

It is important to note that results from an individual clinical study are intended to evaluate efficacy and safety within a specific study population, treatment regimen, and observation period. The findings should not be interpreted as applying universally to all patients with atopic dermatitis. In actual clinical practice, treatment should be based on the approved indication, the current product labeling, and the judgment of qualified healthcare professionals.

Overall, the Phase III study provided clinical evidence supporting the addition of mild-to-moderate atopic dermatitis as an indication for ruxolitinib phosphate cream in China. The indication expansion therefore has a clinical research basis in addition to its regulatory approval.

During actual treatment, an appropriate therapeutic approach should be selected according to the individual patient’s condition and the assessment of a qualified healthcare professional.

✨ It is also worth noting that the application for the new atopic dermatitis indication had previously been included in the priority review pathway of the Center for Drug Evaluation (CDE) of the NMPA. According to an announcement from China Medical System Holdings, the application entered the priority review process because it was considered a new pediatric drug product, dosage form, or specification designed to meet the physiological characteristics of children.

This means that the regulatory review considered not only the treatment needs associated with mild-to-moderate atopic dermatitis, but also factors related to pediatric medication. The inclusion of children aged 2 years and older therefore represents an important component of the newly approved indication.

From Vitiligo to Atopic Dermatitis: Further Expansion of Product Indications

The development of ruxolitinib phosphate cream in China has followed a relatively clear path of indication expansion. In January 2026, the product received an indication related to vitiligo. In September 2026, it gained an additional indication for mild-to-moderate atopic dermatitis, expanding its approved use in China from a single dermatological condition to another common inflammatory skin disease.

The development can also be viewed in the context of the broader trend that ruxolitinib phosphate cream gains new indication in different therapeutic settings as clinical research and regulatory evaluations progress.

Although vitiligo and atopic dermatitis are both dermatological conditions, they are distinct diseases with different clinical manifestations and treatment needs. Vitiligo is primarily associated with dysfunction of melanocytes and immune-related mechanisms, while atopic dermatitis is characterized by chronic inflammation and immune dysregulation. Therefore, the two indications should not be considered interchangeable. Each indication requires supporting clinical evidence and specific regulatory approval.

From a drug development perspective, the investigation of the same targeted therapy across different diseases reflects continued research into the therapeutic potential of relevant immune signaling pathways. From a product development and commercialization perspective, indication expansion means that the medicine may cover a broader range of specialized treatment areas, subject to regulatory approval in each market.

Therefore, while the new atopic dermatitis indication represents an important addition to the approved uses of ruxolitinib phosphate cream in China, this development can also be understood in the context of the product’s previously established application in dermatology. The expansion from vitiligo to mild-to-moderate atopic dermatitis illustrates how ruxolitinib phosphate cream gains new indication through continued clinical research and regulatory evaluation, while the specific use of the product remains dependent on the approved indication and applicable product labeling.

DengYue RX: Supporting Supply and Procurement Connections for Innovative Dermatology Medicines

With the addition of the new atopic dermatitis indication for ruxolitinib phosphate cream, demand for product information and supply inquiries from healthcare institutions, pharmacies, distributors, and other qualified professional procurement customers may also increase. For prescription medicines of this type, accurately confirming the product name, dosage form, strength, packaging, required quantity, and destination is an important basis for supply inquiries.

DengYue RX focuses on pharmaceutical supply and cross-border pharmaceutical supply chain services. Based on information provided by professional customers, including the INN/generic name, brand name, dosage form, strength, packaging, required quantity, and destination, DengYue RX can assist with product information inquiries and supply requirement consultations.

For dermatology prescription medicines such as ruxolitinib phosphate cream, actual supply availability needs to be confirmed based on factors including product source, inventory, procurement eligibility, and the regulatory requirements of the destination country or region. For cross-border procurement, additional considerations may include export regulations, destination import policies, prescription requirements, customs clearance documentation, and transportation conditions.

DengYue RX provides pharmaceutical supply, procurement connections, and related supply chain support. These services do not replace diagnosis, prescribing, or individualized treatment decisions by healthcare professionals. The use of any medicine should follow the applicable approved product labeling and professional medical guidance.

Conclusion

🔎 The expansion of the indication for ruxolitinib phosphate cream reflects the continued development of targeted treatment approaches in the field of dermatological immunology. For patients with atopic dermatitis, disease management involves more than controlling symptoms. Appropriate treatment should take into account factors such as patient age, disease severity, previous treatment response, and individual treatment circumstances. As a result, the appropriate integration of different treatment approaches remains an important part of long-term disease management.

As innovative medicines continue to enter clinical practice, healthcare institutions, pharmacies, and professional procurement customers need to consider not only clinical evidence and approved indications, but also accurately understand a product’s regulatory approval status, eligible patient population, dosage and packaging information, and regulatory requirements across different markets. This information is particularly important when evaluating pharmaceutical supply and procurement requirements in an international context.

FAQ About Ruxolitinib Phosphate Cream Gains New Indication